摘要: |
[目的] 了解Aurora-A基因在卵巢癌细胞中的表达情况,寻找显示卵巢癌恶性程度的肿瘤标记物。[方法]采用半定量RT-PCR、Western blot检测卵巢上皮浆液性囊腺癌细胞(HO-8910)与其高转移亚株(HO-8910PM)细胞株Aurora-A 在mRNA和蛋白表达情况;借助流式细胞仪观察两种卵巢癌细胞DNA含量,并分析Aurora-A表达的相关性。[结果]两种细胞株HO-8910、HO-8910PM半定量RT-PCR结果发现,Aurora-A/β-actin比值分别为:0.95与0.98(P<0.05); Western blot结果显示Aurora-A/β-actin比值分别为: 1.24与1.58(P<0.01)。细胞DNA 含量的检测结果,细胞含有四倍体 (4N)的细胞比例分别为21.63%和30.15%,其多倍体(>4N)细胞的比例分别为2.20%与7.16%(P<0.01)。[结论]在两种卵巢癌细胞中,Aurora-A 基因mRNA与蛋白高表达;两种细胞株Aurora-A基因表达的高低与其细胞DNA含量有相关性,尤其与异倍体的形成有关; Aurora-A基因表达卵巢癌细胞的恶性程度有关。 |
关键词: Aurora-A 多倍体 卵巢癌 癌基因 |
DOI:10.11724/jdmu.2006.05.02 |
分类号:R737.31 |
基金项目: |
|
Expression significances of Aurora-A kinase in human ovarian carcinoma cell lines |
ZOU Zhong-wen1, HU Xue-min2, SU Hong1, ZOU Li-juan1
|
1.The Second Affiliated Hospital of Dalian Medical University,Dalian 116027,China;2.General Hospital of Caac,Beijing,100025,China
|
Abstract: |
[Objective] To investigate the expression of Aurora-A in ovarian carcinoma cell lines and to find the tumor marker which show the malignant level of ovarian carcinoma.[Methods] The expressions of Aurora-A in ovarian carcinoma cell lines(HO-8910,HO-8910PM) in mRNA, protein level were examined by RT-PCR and Western-blot;and the association of Aurora-A expression with DNA content in two ovarian carcinoma cell lines was analyzed by flow cytometry. [Results] In HO-8910 and HO-8910 PM ,the ratios of Aurora-A/β-actin were 0.95 and 0.98 respectively (P<0.05) by RT-PCR;while 1.24 and 1.58 by western blot (P<0.01). The proportion of cells with 4N DNA content in HO-8910 and HO-8910PM were 21.63% and 30.15% respectively, the proportion with >4N DNA content were 2.20% and 7.16% respectively (P <0.01). [Conclusion]Aurora-A was overexpressed in ovarian carcinoma cell lines in mRNA and protein level.The overexpression of Aurora -A in two ovarian carcinoma cell lines has correlation to the DNA content especially with the formation of the heteroploid; The expression of Aurora-A relationed to the
malignancy level of ovarian carcinoma. |
Key words: Aurora-A polyploidy ovarian-carcinoma oncogene |